Cm Management, LLC Nektar Therapeutics Transaction History

Cm Management, LLC

$115 Million
Q1 2024

A detailed history of Cm Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Cm Management, LLC holds 939,847 shares of NKTR stock, worth $1.17 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares

939,847

Previous 939,847 -0.0%

Holding current value

$1.17 Million

Previous $526,000 66.16%

% of portfolio

0.76%

Previous 0.44%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.42 - $0.57 $58,735 - $79,712	139,847 Added 17.48%	939,847 $526,000
Q3 2023 Nov 07, 2023	BUY	$0.51 - $1.05 $25,500 - $52,500	50,000 Added 6.67%	800,000 $480,000
Q2 2023 Aug 04, 2023	BUY	$0.53 - $1.03 $185,500 - $360,500	350,000 Added 87.5%	750,000 $431,000
Q1 2023 May 08, 2023	BUY	$0.64 - $3.15 $176,000 - $866,250	275,000 Added 220.0%	400,000 $281,000
Q4 2022 Feb 09, 2023	BUY	$2.03 - $4.28 $152,249 - $321,000	75,000 Added 150.0%	125,000 $283,000

Q3 2022 Nov 04, 2022	SELL	$3.04 - $5.14 $228,000 - $385,500	-75,000 Reduced 60.0%	50,000 $160,000
Q2 2022 Aug 08, 2022	BUY	$3.17 - $6.17 $158,500 - $308,500	50,000 Added 66.67%	125,000 $475,000
Q1 2022 May 09, 2022	BUY	$4.16 - $13.72 $208,000 - $686,000	50,000 Added 200.0%	75,000 $404,000
Q4 2021 Feb 02, 2022	SELL	$10.83 - $18.41 $270,750 - $460,250	-25,000 Reduced 50.0%	25,000 $338,000
Q1 2021 May 12, 2021	BUY	$16.56 - $25.46 $248,399 - $381,900	15,000 Added 42.86%	50,000 $1 Million
Q4 2020 Feb 04, 2021	BUY	$15.77 - $19.03 $551,950 - $666,050	35,000 New	35,000 $595,000

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.

Account

Cm Management, LLC Nektar Therapeutics Transaction History